|
|
|
|
Ms Antisense Drug Shows Early Promise, But Long-term Benefit Remains Unknown
A new study suggests another way to target VLA-4 as a strategy for relapsing MS: use antisense oligonucleotides to prevent the key cell adhesion molecule from being produced in the first place.SEATTLE-Inhibiting migration of lymphocytes...
|
|
|
Overcoming Research Challenges Necessary to Better Understand Course of TBI, Speakers Say
Experts said TBI research could benefit from better animal models, and well-designed trials on brain pharmacokinetics, biomarkers, and surrogate endpoints.A RLINGTON, VA-In an era when mission-motivated military service personnel and...
|
|
|
Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry
SHANGHAI, July 3 /PRNewswire-Asia/ -- Sundia MediTech, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr.Chen Chen has been appointed Senior Vice President of...
|
|
|
Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry
SHANGHAI, July 3 /PRNewswire-Asia/ -- Sundia MediTech, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr.Chen Chen has been appointed Senior Vice President of...
|
|
|
Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry
SHANGHAI , July 3 /PRNewswire-Asia/ -- Sundia MediTech, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr.Chen Chen Prior to joining Sundia, Dr. Chen worked at...
|
|
|
Biopharmaceutical Drug Developers topic: Detection of protein aggregation by AF4/MALS
The formation of aggregates in biopharmaceuticals such as monoclonal antibodies (MAbs), represents a severe problem, which has also been addressed by FDA authorities recently.Particularly their potential to trigger or enhance undesirable...
|
|
|
EC lifts treatment restrictions on Neupro
UCB announced that Neupro (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson's disease in Europe and is newly available for the symptomatic treatment of moderate to severe idiopathic Restless Legs...
|
|
|
Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry
SHANGHAI, July 3 /PRNewswire-Asia/ -- Sundia MediTech, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr.Chen Chen has been appointed Senior Vice President of...
|
|
|
Export Development Canada Contributes Usd 50 Million Towards Biovail Facility
Export Development Canada (EDC) today announced it has committed USD 50 million towards a USD 400 million revolving credit facility for Biovail Corporation (Biovail), Canadas largest publicly traded pharmaceutical company.Biovail is a...
|
|
|
Rexahn Pharmaceuticals Inks a Development and Commercialization Pact
(Close-Up Media via COMTEX) -- RNN | Quote | Chart | News | PowerRating -- Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential oncology and CNS therapeutics, announced that it has signed an...
|
|
|
CNS Response Files Action Against Its Former CEO
CNS Response, Inc.(OTCBB: CNSO) today announced that it has filed an action in the United States District Court for the Central District of California against Len Brandt, the Company's former CEO, who was terminated on April 10,...
|
|
|
CNS Response Provides Third Quarter Corporate Update
Companies mentioned in this article: CNS Response, Inc.COSTA MESA, CA -- (Marketwire) -- 07/02/09 -- CNS Response, Inc. (OTCBB: CNSO) today announced that its annual meeting of stockholders will be held in September 2009.
|
|
|
Important Modulator Of Immune Cell Entry Into The Brain Discovered
Researchers in Berlin, Germany have ameliorated inflammation of the brain in mice caused by immune cells.A receptor they discovered on the surface of T cells in the central nervous system (CNS) plays the key role. The researchers...
|
|
|
Biopharmaceutical Drug Developers topic: Detection of protein aggregation by AF4/MALS
The formation of aggregates in biopharmaceuticals such as monoclonal antibodies (MAbs), represents a severe problem, which has also been addressed by FDA authorities recently.Particularly their potential to trigger or enhance undesirable...
|
|
|
Graceway Acquires Dermatological Compounds from Pfizer
GEN News Highlights GEN News Highlights Graceway Pharmaceuticalsobtained commercialization rights to three dermatological molecules from Pfizer.The acquisition and license agreement includes related transferred or licensed intellectual...
|
|
|
- DEALS - INC Research Acquires Phase II-IV Operations of MDS Pharma
RALEIGH, N.C.- INC Research(R), Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, announced it has completed the acquisition of the Phase II-IV operations (Global Clinical...
|
|
|
EDC contributes USD 50 million towards Biovail facility
(Canada NewsWire via COMTEX) -- BVF | Quote | Chart | News | PowerRating -- Export Development Canada (EDC) today announced it has committed USD 50 million towards a USD 400 million revolving credit facility for Biovail Corporation (Biovail)...
|
|
|
EDC contributes USD 50 million towards Biovail facility
'Biovail is a strong Canadian company that is making significant progress in growing its business, and EDC is pleased to play a financial role in their efforts through our new domestic powers,' said Stephen Poloz, Senior Vice-President,...
|
|
|
EDC contributes USD 50 million towards Biovail facility
OTTAWA, July 2 /CNW Telbec/ - Export Development Canada (EDC) today announced it has committed USD 50 million towards a USD 400 million revolving credit facility for Biovail Corporation (Biovail), Canada's largest publicly traded...
|
|
|
INC Research makes it official with MDS' Phase II-IV Unit
INC Research, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, today announced it has completed the acquisition of the Phase II-IV operations (Global Clinical Development)...
|
|
|
INC Research makes it official with MDS' Phase II-IV Unit
INC Research, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, today announced it has completed the acquisition of the Phase II-IV operations (Global Clinical Development)...
|
|
|
Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fr
1Department of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, FL, USA 2Department of Neuroscience, University of Florida College of Medicine, Gainesville, FL, USA Correspondence: Professor DC...
|
|
|
Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fr
Fragile X syndrome (FXS) is caused by a mutation that silences the fragile X mental retardation gene (FMR1), which encodes the fragile X mental retardation protein (FMRP).To determine whether FMRP replacement can rescue phenotypic...
|
|
|
Methods for treatment of nocturia
Title: United States Patent: 7,547,688 Inventors: Araki; Tohru (Okayama, JP) Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP) Appl.No.: 11/906,564 Filed: October 3, 2007 A method for the treatment of nocturia which consists of...
|
|
|
The Top 75: Blue Diesel
Many agencies heavy on digital and interactive are claiming to have spotted a silver lining in the cloudy economic landscape of 2009.Blue Diesel reports that the lining is golden. We've seen a 20-plus percent growth in '09 over '08, and...
|
